AEON
AEON Biopharma, Inc.
0.81
700 x 0.81
500 x 0.81
bid
ask
-
0.02
2.62%
10:06 AM
timesize
| Ytd | -26.40% | |
| 1y | 61.27% |
0.81
day range
0.81
0.46
52 week range
1.45
| Open | 0.81 | Prev Close | 0.83 | Low | 0.81 | High | 0.81 | Mkt Cap | 21.30M |
| Vol | 3.58K | Avg Vol | 100.53K | EPS | -3.95 | P/E | N/A | Forward P/E | -0.84 |
| Beta | 0.40 | Short Ratio | 1.60 | Inst. Own | 33.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.00 | 200-d Avg | 0.95 | 1yr Est | 5.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.16 | -0.16 | N/A | N/A |
| 2024-08-12 | 2024-06 | -0.19 | N/A | N/A | N/A |
| 2024-08-12 | 2024-06 | -0.19 | -0.16 | 0.03 | 15.79% |
| 2024-05-14 | 2024-03 | -0.31 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.31 | -0.28 | 0.03 | 9.68% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-10-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-29 | CARTER ERIC G | Director | 36.02K | Stock Award(Grant) |
| 2024-08-29 | FISCHER JOST | Director | 96.79K | Stock Award(Grant) |
| 2024-08-29 | FORTH MARC | Chief Executive Officer | 750.55K | Stock Award(Grant) |
| 2024-08-29 | OH CHAD M.D. | Officer | 292.55K | Stock Award(Grant) |
| 2024-08-29 | PALMISANO ROBERT J | Director | 36.02K | Stock Award(Grant) |
| 2023-07-20 | PRIVETERRA SPONSOR, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Polar Asset Management Partners Inc. | 3.60M | 2.09M | 9.01% |
| 2024-09-29 | Blue Owl Capital Holdings LP | 3.34M | 1.94M | 8.36% |
| 2024-09-29 | Vanguard Group Inc | 751.34K | 437.21K | 1.88% |
| 2024-09-29 | Formidable Asset Management, Llc | 389.78K | 226.81K | 0.98% |
| 2024-09-29 | Blackrock Inc. | 265.15K | 154.29K | 0.66% |
| 2024-09-29 | Ikarian Capital, LLC | 257.98K | 150.12K | 0.65% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 414.90K | 241.43K | 1.04% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 320.90K | 186.73K | 0.80% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 145.37K | 84.59K | 0.36% |
| 2024-10-30 | iShares Micro Cap ETF | 54.42K | 31.67K | 0.14% |
| 2024-10-30 | Fidelity Total Market Index Fund | 46.26K | 26.92K | 0.12% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 35.14K | 20.45K | 0.09% |
Split
| Split | Date |
|---|---|
| 1 : 72 | 2025-02-26 |
